FIELD: medicine.
SUBSTANCE: invention relates to methods and compositions for therapeutic and diagnostic application in treating diseases and disorders, caused by or associated with neurofibrillar balls. Antibodies, which specifically recognize and bind to phosphorylated pathological conformers of Tau-protein, are described, as well as methods and compositions containing said antibodies for therapeutic and diagnostic application in treating tauopathies, including Alzheimer's disease (AD). Disclosed antibodies bind phospho-epitope of mammalian Tau-protein with dissociation constant less than 10 nM and do not bind with appropriate not phosphorylated epitope.
EFFECT: invention extends the range of products for treating tauopathies.
21 cl, 10 dwg, 13 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHOSPHO-SPECIFIC ANTIBODIES RECOGNIZING TAU | 2012 |
|
RU2639537C2 |
| HUMANIZED TAU-ANTIBODY | 2013 |
|
RU2644242C2 |
| PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2582916C2 |
| USING ANTI-TAU PS422 ANTIBODY FOR TREATING CEREBROPATHIES | 2010 |
|
RU2536247C2 |
| MONOCLONAL BODY AGAINST AMYLOID BETA | 2008 |
|
RU2571856C2 |
| ANTI-TAU ANTIBODIES AND METHODS OF USE | 2014 |
|
RU2661111C2 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2604181C2 |
| PROLACTIN RECEPTOR BINDING PROTEINS AND THEIR USE | 2013 |
|
RU2664463C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| ANTIBODIES, SPECIFIC TO HYPERPHOSPHORYLATED TAU-PROTEIN, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2727911C2 |
